1700016D06Rik Inhibitors
Chemical inhibitors of the protein 1700016D06Rik act through various biochemical pathways to modulate its activity within cells. Staurosporine is a potent kinase inhibitor, known for its ability to broadly target protein kinases, and can thus inhibit the phosphorylation of 1700016D06Rik, affecting its activity if phosphorylation is a crucial modification for its function. Similarly, both LY294002 and Wortmannin target PI3K, a key component of intracellular signaling pathways. These inhibitors can suppress the activity of PI3K, which may indirectly influence the role of 1700016D06Rik by preventing its activation or recruitment to essential cellular signaling complexes. In a related mechanism, Rapamycin focuses on mTOR, a central regulator of cell growth, which can impinge upon the functionality of 1700016D06Rik by disrupting processes it may be involved in.
Inhibitors like PD98059 and U0126 are specifically designed to inhibit MEK, which subsequently prevents the activation of ERK, a kinase that plays a pivotal role in cell signaling. By impeding the MEK/ERK pathway, these inhibitors can indirectly lead to a decrease in 1700016D06Rik activity. Similarly, SB203580 targets p38 MAP Kinase, a molecule that responds to stress stimuli, and by inhibiting it, SB203580 may impact the role of 1700016D06Rik in related signaling pathways. SP600125 acts upon JNK, another kinase involved in stress and cytokine signaling, and its inhibition can affect 1700016D06Rik if it operates downstream or in concert with the JNK pathway. PP2 and Dasatinib serve as kinase inhibitors with a broader range, targeting Src family kinases and Bcr-Abl, respectively. The Src family of kinases is involved in multiple signaling cascades, and their inhibition could result in diminished 1700016D06Rik activity. Lastly, Y-27632 and Palbociclib inhibit ROCK and CDK4/6 kinases, respectively, with potential effects on 1700016D06Rik activity if it is engaged in ROCK-mediated cytoskeletal dynamics or CDK4/6-regulated cell cycle progression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits a broad spectrum of protein kinases, which may include kinases that phosphorylate 1700016D06Rik, thereby directly inhibiting its phosphorylation-dependent activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor; since PI3K signaling can regulate a multitude of cellular functions including those involving 1700016D06Rik, inhibition of PI3K can lead to a downstream inhibition of 1700016D06Rik activity by preventing its activation or recruitment to signaling complexes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin operates by irreversibly inhibiting PI3K. Given that PI3K activity can control various cellular processes that might implicate 1700016D06Rik, the inhibition of PI3K by Wortmannin could lead to a reduction in 1700016D06Rik activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator in cell growth and proliferation. Since mTOR pathways can regulate protein synthesis and other cellular processes in which 1700016D06Rik might be involved, its inhibition can lead to the functional inhibition of 1700016D06Rik by halting the processes that it facilitates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which in turn inhibits ERK activation. As ERK can regulate various cellular functions, including those associated with 1700016D06Rik, inhibition of this pathway can result in the functional inhibition of 1700016D06Rik by preventing its participation in MEK/ERK-mediated signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents ERK activation. By inhibiting MEK, U0126 can indirectly inhibit the function of 1700016D06Rik by blocking the signaling pathways in which it might be involved, particularly if 1700016D06Rik functions downstream of, or in parallel to, MEK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP Kinase. Since p38 MAPK is involved in response to stress stimuli and cytokines, its inhibition can lead to the functional inhibition of 1700016D06Rik if 1700016D06Rik's activity is linked to the p38 MAPK signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, and by doing so, it can inhibit the function of 1700016D06Rik if 1700016D06Rik is a downstream target in the JNK signaling pathway or is modulated by proteins that are regulated by JNK activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. The Src family of kinases can regulate numerous signaling pathways, and if 1700016D06Rik is part of or is regulated by these pathways, inhibition by PP2 can lead to a decrease in 1700016D06Rik activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum protein kinase inhibitor with activity against Src family kinases and Bcr-Abl. If 1700016D06Rik activity is mediated through these kinases, dasatinib can functionally inhibit 1700016D06Rik by inhibiting the kinases that regulate it. | ||||||